NASDAQ:TIL - Instil Bio Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $29.50
  • Forecasted Upside: 66.10 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$17.76
▲ +1.22 (7.38%)
1 month | 3 months | 12 months
Get New Instil Bio Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TIL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TIL

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$29.50
▲ +66.10% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Instil Bio in the last 3 months. The average price target is $29.50, with a high forecast of $32.00 and a low forecast of $23.00. The average price target represents a 66.10% upside from the last price of $17.76.

Buy

The current consensus among 5 investment analysts is to buy stock in Instil Bio.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/23/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/22/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/20/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/18/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/17/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/17/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/16/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/15/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/26/2021Morgan StanleyLower Price TargetEqual Weight$24.00 ➝ $23.00N/A
i
4/19/2021Truist SecuritiesInitiated CoverageBuy$32.00N/A
i
4/19/2021CowenInitiated CoverageOutperformN/A
i
4/19/2021Morgan StanleyInitiated CoverageEqual Weight$24.00N/A
i
4/19/2021Jefferies Financial GroupInitiated CoverageBuy$31.00N/A
i
4/13/2021Truist SecuritiesInitiated CoverageBuy$32.00N/A
i
4/13/2021Jefferies Financial GroupInitiated CoverageBuy$31.00N/A
i
4/13/2021Morgan StanleyInitiated CoverageEqual Weight$24.00N/A
i
4/13/2021CowenInitiated CoverageOutperformN/A
i
4/13/2021TruistInitiated CoverageBuy$32.00N/A
i
(Data available from 6/16/2016 forward)
Instil Bio logo
Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 (FOLR1) with indications, including gynecological, non-small cell lung cancer, and others. The company was incorporated in 2018 and is based in Dallas, Texas.
Read More

Today's Range

Now: $17.76
$16.54
$17.85

50 Day Range

MA: $18.34
$15.31
$24.36

52 Week Range

Now: $17.76
$14.42
$29.49

Volume

379,443 shs

Average Volume

341,961 shs

Market Capitalization

$2.29 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Instil Bio?

The following sell-side analysts have issued reports on Instil Bio in the last year: Cowen Inc, Jefferies Financial Group Inc., Morgan Stanley, Truist, and Truist Securities.
View the latest analyst ratings for TIL.

What is the current price target for Instil Bio?

4 Wall Street analysts have set twelve-month price targets for Instil Bio in the last year. Their average twelve-month price target is $29.50, suggesting a possible upside of 66.1%. Truist has the highest price target set, predicting TIL will reach $32.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $23.00 for Instil Bio in the next year.
View the latest price targets for TIL.

What is the current consensus analyst rating for Instil Bio?

Instil Bio currently has 1 hold rating and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe TIL will outperform the market and that investors should add to their positions of Instil Bio.
View the latest ratings for TIL.

What other companies compete with Instil Bio?

How do I contact Instil Bio's investor relations team?

Instil Bio's physical mailing address is CONTINENTAL BUILDING 25 CHURCH STREET, HAMILTON D0, HM1Z. The company's listed phone number is 240 676 3715 and its investor relations email address is [email protected] The official website for Instil Bio is www.tillcap.com.